These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 19789295

  • 1. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [Abstract] [Full Text] [Related]

  • 2. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 3. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.
    Cochrane Database Syst Rev; 2018 May 09; 5(5):CD009069. PubMed ID: 29740819
    [Abstract] [Full Text] [Related]

  • 5. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N.
    Cochrane Database Syst Rev; 2019 Nov 22; 2019(11):. PubMed ID: 31755549
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J.
    Lancet; 2007 May 19; 369(9574):1693-702. PubMed ID: 17512854
    [Abstract] [Full Text] [Related]

  • 7. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group.
    N Engl J Med; 2007 May 10; 356(19):1915-27. PubMed ID: 17494925
    [Abstract] [Full Text] [Related]

  • 8. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
    BMJ Open; 2017 Aug 18; 7(8):e015867. PubMed ID: 28821519
    [Abstract] [Full Text] [Related]

  • 10. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPV Vaccine Study.
    N Engl J Med; 2015 Feb 19; 372(8):711-23. PubMed ID: 25693011
    [Abstract] [Full Text] [Related]

  • 11. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.
    Lancet; 2017 Nov 11; 390(10108):2143-2159. PubMed ID: 28886907
    [Abstract] [Full Text] [Related]

  • 12. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, FUTURE I and II Study Group.
    BMJ; 2012 Mar 27; 344():e1401. PubMed ID: 22454089
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
    FUTURE II Study Group.
    J Infect Dis; 2007 Nov 15; 196(10):1438-46. PubMed ID: 18008221
    [Abstract] [Full Text] [Related]

  • 14. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun 15; 16(89):91-4. PubMed ID: 17582921
    [Abstract] [Full Text] [Related]

  • 15. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.
    Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Muñoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, Esser MT, Giacoletti K, James M, Taddeo F, Vuocolo S, Barr E.
    J Eur Acad Dermatol Venereol; 2009 Oct 15; 23(10):1147-55. PubMed ID: 19453788
    [Abstract] [Full Text] [Related]

  • 16. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
    Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A.
    Br J Cancer; 2011 Jun 28; 105(1):28-37. PubMed ID: 21629249
    [Abstract] [Full Text] [Related]

  • 17. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L, Hopkins L, Hutton B, Fergusson D.
    CMAJ; 2007 Aug 28; 177(5):469-79. PubMed ID: 17671238
    [Abstract] [Full Text] [Related]

  • 18. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 28; 13(1):89-99. PubMed ID: 22075171
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
    Yoshikawa H, Ebihara K, Tanaka Y, Noda K.
    Cancer Sci; 2013 Apr 28; 104(4):465-72. PubMed ID: 23331518
    [Abstract] [Full Text] [Related]

  • 20. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
    Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group.
    Int J Cancer; 2016 Dec 15; 139(12):2812-2826. PubMed ID: 27541373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.